Stocks › ROIV
Roivant Sciences Ltd.
ROIV·Nasdaq·USD
$35.53
-0.25 (-0.70%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
ROIV
Roivant Sciences Ltd. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ROIVS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of ROIV by members of U.S. Congress · 4 on record · 3 in the last 12 months
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Lisa C. McClainHouse · R · MI |
ROIVRoivant Sciences Ltd. · Stock |
Sale $1,001 - $15,000 |
Nov 21, 2025 | Oct 30, 2025 | Filing ↗ |
| Lisa C. McClainHouse · R · MI |
ROIVRoivant Sciences Ltd. · Stock |
Purchase $1,001 - $15,000 |
Nov 21, 2025 | Oct 30, 2025 | Filing ↗ |
| Lisa C. McClainHouse · R · MI |
ROIVRoivant Sciences Ltd. · Stock |
Sale $1,001 - $15,000 |
Nov 21, 2025 | Oct 31, 2025 | Filing ↗ |
| Lisa C. McClainHouse · R · MI |
ROIVRoivant Sciences Ltd. · Stock |
Purchase $1,001 - $15,000 |
Aug 13, 2025 | Jun 17, 2025 | Filing ↗ |
Whale Activity
Position changes in ROIV reported for 2026-09-30 by 1 tracked institutional filer
- Increased0
- New0
- Held0
- Decreased0
- Closed0
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| Two Seas Capital LP | 7.3M | $267.9M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by ROIV insiders, by quarter · Form 4
Recent Insider Transactions
770 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Epperly Melissa B,Director · Director | Sale | −900 | $36.57 | $33K | Oct 1, 2026 | Form 4 ↗ |
| Epperly Melissa B,Director · Director | Sale | −16.9K | $36.08 | $608K | Oct 1, 2026 | Form 4 ↗ |
| Venker EricPresident & Immunovant CEO | Sale | −200.0K | $36.62 | $7.3M | Sep 30, 2026 | Form 4 ↗ |
| Epperly Melissa B,Director · Director | Sale | −600 | $40.38 | $24K | Sep 15, 2026 | Form 4 ↗ |
| Epperly Melissa B,Director · Director | Sale | −4,338 | $39.65 | $172K | Sep 15, 2026 | Form 4 ↗ |
| Fitzgerald MeghanDirector · Director | Sale | −4,712 | $39.68 | $187K | Sep 15, 2026 | Form 4 ↗ |
| Fitzgerald MeghanDirector · Director | Sale | −400 | $40.45 | $16K | Sep 15, 2026 | Form 4 ↗ |
| Fitzgerald MeghanDirector · Director | Sale | −20.0K | $39.90 | $798K | Sep 8, 2026 | Form 4 ↗ |
| Venker EricPresident & Immunovant CEO | Sale | −33.8K | $36.44 | $1.2M | Aug 28, 2026 | Form 4 ↗ |
| Venker EricPresident & Immunovant CEO | Sale | −166.2K | $35.63 | $5.9M | Aug 28, 2026 | Form 4 ↗ |
| Sukhatme MayukhPresident & CIO · Director | Sale | −144.8K | $36.48 | $5.3M | Aug 21, 2026 | Form 4 ↗ |
| Sukhatme MayukhPresident & CIO · Director | Sale | −17.5K | $37.30 | $653K | Aug 20, 2026 | Form 4 ↗ |
| Sukhatme MayukhPresident & CIO · Director | Sale | −172.9K | $37.17 | $6.4M | Aug 19, 2026 | Form 4 ↗ |
| Sukhatme MayukhPresident & CIO · Director | Sale | −31.8K | $37.18 | $1.2M | Aug 18, 2026 | Form 4 ↗ |
| Sukhatme MayukhPresident & CIO · Director | Sale | −105.1K | $36.59 | $3.8M | Aug 18, 2026 | Form 4 ↗ |
| Sukhatme MayukhPresident & CIO · Director | Sale | −284.7K | $36.25 | $10.3M | Aug 17, 2026 | Form 4 ↗ |
| Sukhatme MayukhPresident & CIO · Director | Sale | −243.2K | $36.23 | $8.8M | Aug 14, 2026 | Form 4 ↗ |
| Venker EricPresident & Immunovant CEO | Sale | −200.0K | $34.95 | $7.0M | Jul 27, 2026 | Form 4 ↗ |
| Fitzgerald MeghanDirector · Director | Sale | −10.0K | $34.90 | $349K | Jun 30, 2026 | Form 4 ↗ |
| MANCHESTER KEITH SDirector | Sale | −200.0K | $35.45 | $7.1M | Jun 30, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding ROIV · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 16.0M | $565.8M | 0.02% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 11.5M | $408.6M | 0.22% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 6.7M | $235.6M | 0.50% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 5.2M | $182.9M | 0.19% | Jun 30, 2026 |
| Invesco S&P MidCap Momentum ETF Invesco Exchange-Traded Fund Trust | 5.2M | $177.0M | 2.47% | Jul 31, 2026 |
| VANGUARD EXPLORER FUND | 3.0M | $100.7M | 0.46% | Jul 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF Dimensional ETF Trust | 1.2M | $39.5M | 0.08% | Jul 31, 2026 |
| iShares Russell 1000 Value ETF iShares Trust | 1.1M | $38.7M | 0.05% | Jun 30, 2026 |
| VANGUARD HEALTH CARE INDEX FUND VANGUARD WORLD FUND | 1.1M | $33.8M | 0.18% | May 31, 2026 |
| VANGUARD S&P MID-CAP 400 INDEX FUND VANGUARD ADMIRAL FUNDS | 719.5K | $21.6M | 0.39% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list ROIV's shares (CUSIP G76279101), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Morgan Stanley Investment Management Inc.SCHEDULE 13G/A · passive (13G) · 39.4M shares5.5%
Aug 13, 2026 · ↗ - Morgan StanleySCHEDULE 13G/A · passive (13G) · 40.7M shares5.7%
Aug 13, 2026 · ↗ - Morgan Stanley Investment Management Inc.SCHEDULE 13G/A · passive (13G) · 48.3M shares6.7%
May 12, 2026 · ↗ - Morgan StanleySCHEDULE 13G/A · passive (13G) · 49.5M shares6.9%
May 12, 2026 · ↗ - Ramaswamy VivekSCHEDULE 13G/A · passive (13G) · 25.5M shares3.6%
May 6, 2026 · ↗ - Morgan Stanley Investment Management Inc.SCHEDULE 13G/A · passive (13G) · 54.4M shares7.8%
Feb 11, 2026 · ↗ - Morgan StanleySCHEDULE 13G/A · passive (13G) · 55.5M shares8.0%
Feb 11, 2026 · ↗ - Morgan Stanley Investment Management Inc.SCHEDULE 13G · passive (13G) · 36.5M shares5.4%
Aug 7, 2025 · ↗ - Morgan StanleySCHEDULE 13G · passive (13G) · 37.6M shares5.5%
Aug 7, 2025 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming roivant sciences as client
No lobbying filings found naming Roivant Sciences Ltd. as the client.
- THE CONAFAY GROUP, LLCROIVANT SCIENCES, INC. · 2022 Q1—
Filing ↗ - THE CONAFAY GROUP, LLCROIVANT SCIENCES, INC. · 2021 Q4 · BUD, MED$20K
Filing ↗ - THE CONAFAY GROUP, LLCROIVANT SCIENCES, INC. · 2021 Q3 · BUD, MED$20K
Filing ↗ - BAKER DONELSON BEARMAN CALDWELL & BERKOWITZROIVANT SCIENCES, INC. · 2021 Q2—
Filing ↗ - THE CONAFAY GROUP, LLCROIVANT SCIENCES, INC. · 2021 Q2 · MED, BUD$20K
Filing ↗
Government Contracts
Federal awards to Roivant Sciences Ltd. · USAspending
No federal contract awards found for Roivant Sciences Ltd..
U.S. Patents
Recent USPTO applications naming Roivant Sciences Ltd.
No USPTO patent applications found for Roivant Sciences Ltd..
Annual Financials
From ROIV's 10-K filings · XBRL
No annual XBRL figures on record for ROIV. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in ROIV's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 5.07, 9.01Shareholder voteSep 18, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureSep 8, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsAug 28, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureAug 27, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 20, 2026
EDGAR ↗
About Roivant Sciences Ltd.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersLONDON
IncorporatedD0
SEC CIK0001635088 ↗